Efficacy News and Research

RSS
BDSI to initiate BEMA Buprenorphine Phase 3 program following positive End-of-Phase 2 meeting with FDA

BDSI to initiate BEMA Buprenorphine Phase 3 program following positive End-of-Phase 2 meeting with FDA

Reuters examines development progress of microbicide gel to prevent HIV

Reuters examines development progress of microbicide gel to prevent HIV

Lotus receives Chinese SFDA approval for R-Bambuterol Hydrochloride Phase I human clinical trials

Lotus receives Chinese SFDA approval for R-Bambuterol Hydrochloride Phase I human clinical trials

GTC 2010 third fiscal quarter net loss decreases to $4.5 million from $26.2 million

GTC 2010 third fiscal quarter net loss decreases to $4.5 million from $26.2 million

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

MedAvante's centralized ratings to be used in Rexahn's Serdaxin Phase 2a study in MDD patients

TCSPP, Los Angeles launches Forensic Training Institute

TCSPP, Los Angeles launches Forensic Training Institute

ENDOMETRIN Vaginal Insert offers effective luteal support in IVF procedures

ENDOMETRIN Vaginal Insert offers effective luteal support in IVF procedures

HIFU technology effective for treating metastatic liver cancer

HIFU technology effective for treating metastatic liver cancer

Lifestyle intervention programs result in significant weight loss for overweight and severly obese adults

Lifestyle intervention programs result in significant weight loss for overweight and severly obese adults

Study finds association between KRAS p.G13D mutations and cetuximab treatment in colorectal cancer

Study finds association between KRAS p.G13D mutations and cetuximab treatment in colorectal cancer

Oncolytics presents REO 013 clinical trial data for colorectal cancer at International Symposium in Spain

Oncolytics presents REO 013 clinical trial data for colorectal cancer at International Symposium in Spain

PPD and VirtualScopics partner to provide medical imaging services

PPD and VirtualScopics partner to provide medical imaging services

Keryx completes randomization of last patient in Zerenex Phase 3 study for hyperphosphatemia

Keryx completes randomization of last patient in Zerenex Phase 3 study for hyperphosphatemia

India's Trade Minister says EU will take steps to prevent seizure of generic medicines

India's Trade Minister says EU will take steps to prevent seizure of generic medicines

Pfizer's Sutent stands as first-line setting for treating renal cell carcinoma: Survey

Pfizer's Sutent stands as first-line setting for treating renal cell carcinoma: Survey

Tengion presents data on Neo-Kidney Augment at Transplantation's Annual Scientific Exchange

Tengion presents data on Neo-Kidney Augment at Transplantation's Annual Scientific Exchange

Karo Bio reports MSEK 0.0 (5.9) net sales for January-September 2010

Karo Bio reports MSEK 0.0 (5.9) net sales for January-September 2010

Phase II data from resminostat SAPHIRE study to be presented at International Hodgkin Lymphoma Symposium

Phase II data from resminostat SAPHIRE study to be presented at International Hodgkin Lymphoma Symposium

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Sanofi-aventis commences teriflunomide Phase III study in RMS patients treated with interferon beta

Sanofi-aventis commences teriflunomide Phase III study in RMS patients treated with interferon beta

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.